GRI Bio, Inc. (GRI) Form 10-Q — Aug 14, 2026
GRI Bio's Q2 2026 10-Q carries an explicit going-concern warning: management states there is substantial doubt about the company's ability to continue as a going concern, with $10.9 million in cash expected to fund planned operations only through the second quarter of 2027, and only under a plan that excludes the additional dose-ranging and clinical studies GRI-0621 would need. Quarterly results showed a smaller loss as the Phase 2a IPF trial wound down: net loss was $1.6 million versus $2.9 million a year earlier, with R&D spending cut to $0.4 million from $1.9 million after the trial's completion.
Key figures
- Total Assets
- 11380000
- Cash Position
- 10947000
- Shares Outstanding
- 2186115
- Cash runway
- through Q2 2027
- Q2 2025 rd expense
- 1879000
- Q2 2026 ga expense
- 1241000
- Q2 2026 rd expense
- 407000
- Accumulated deficit
- 55337000
- Reverse split ratios
- 1-for-17 (Feb 2025); 1-for-28 (Jan 2026)
- Nasdaq mvls threshold
- 5000000
- Atm shares sold to date
- 1748549
- Atm capacity increased to
- 60000000
- Phase2a patients enrolled
- 35
- Atm gross proceeds to date
- 14379000
- Fvc placebo adjusted gain ml
- 99
- Orphan drug designation date
- June 18, 2026
- Six month financing proceeds
- 7849000
- Atm weighted avg price to date
- 8.22
- Q2 2026 atm weighted avg price
- 2.32
Price after filing
Close on the filing date to close N calendar days later (from $1.67). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.